Publication | Closed Access

High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol

Hematological MalignancyTransplantationMarrow TransplantationMedicineYounger PatientsHematologyImmunologyMyeloma PatientsStem Cell TransplantationStem Cell TherapiesOncologyCell TransplantationHigh-dose Melphalan